Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer

March 27, 2018 – Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab, according to Daiichi Sankyo, the manufacturer of the antibody-drug conjugate. The Sakigake designation from the Ministry of Health, Labor and Welfare gives trastuzumab deruxtecan prioritized consultation, a dedicated review system to support the development … (leggi tutto)